Impax Asset Management Group plc Boosts Holdings in Boston Scientific Corporation $BSX

Impax Asset Management Group plc lifted its stake in Boston Scientific Corporation (NYSE:BSX) by 19.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,727,380 shares of the medical equipment provider’s stock after buying an additional 277,644 shares during the quarter. Impax Asset Management Group plc owned approximately 0.12% of Boston Scientific worth $168,644,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the stock. Vanguard Group Inc. boosted its position in Boston Scientific by 1.9% during the second quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock worth $14,729,575,000 after purchasing an additional 2,545,381 shares in the last quarter. State Street Corp increased its stake in Boston Scientific by 1.1% during the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after buying an additional 713,379 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Boston Scientific by 2.0% during the second quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock valued at $3,466,320,000 after acquiring an additional 622,602 shares during the last quarter. Norges Bank purchased a new position in shares of Boston Scientific in the second quarter valued at approximately $2,089,937,000. Finally, Invesco Ltd. increased its position in shares of Boston Scientific by 1.4% during the second quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider’s stock worth $1,810,022,000 after purchasing an additional 226,578 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,396,580. The trade was a 42.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.50% of the company’s stock.

Boston Scientific Stock Up 0.2%

Shares of NYSE BSX opened at $74.26 on Wednesday. The business has a 50-day moving average of $92.36 and a two-hundred day moving average of $98.24. The company has a market capitalization of $110.09 billion, a price-to-earnings ratio of 38.28, a price-to-earnings-growth ratio of 1.55 and a beta of 0.67. Boston Scientific Corporation has a 1 year low of $73.92 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. The business had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.96%. The company’s revenue was up 15.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on BSX shares. Needham & Company LLC decreased their price target on shares of Boston Scientific from $121.00 to $97.00 and set a “buy” rating on the stock in a research note on Thursday, February 5th. Oppenheimer reduced their price target on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a report on Friday, January 16th. Citigroup dropped their price target on shares of Boston Scientific from $130.00 to $102.00 and set a “buy” rating for the company in a research note on Thursday, February 5th. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Truist Financial cut their price objective on Boston Scientific from $120.00 to $95.00 and set a “buy” rating for the company in a research report on Thursday, February 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $109.43.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.